Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsPreferred Shares RepurchasedShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Gains from Investment Securities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Gains from Investment Securities for 14 consecutive years, with $9334.0 as the latest value for Q1 2026.

  • Quarterly Gains from Investment Securities rose 25.0% to $9334.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9334.0 through Jan 2026, up 25.0% year-over-year, with the annual reading at $1.2 million for FY2025, 26.46% up from the prior year.
  • Gains from Investment Securities for Q1 2026 was $9334.0 at PharmaCyte Biotech, down from $154596.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $281936.0 in Q1 2023, with the low at -$337612.0 in Q2 2023.
  • Average Gains from Investment Securities over 5 years is $66829.6, with a median of $43468.0 recorded in 2022.
  • The sharpest move saw Gains from Investment Securities skyrocketed 11392.19% in 2022, then plummeted 99.48% in 2024.
  • Over 5 years, Gains from Investment Securities stood at $37936.0 in 2022, then soared by 637.56% to $279802.0 in 2023, then tumbled by 99.48% to $1466.0 in 2024, then surged by 10445.43% to $154596.0 in 2025, then plummeted by 93.96% to $9334.0 in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $9334.0, $154596.0, and $152594.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.